Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 1 Sept 2021

Na Seunghee, Kim Taewon

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia
Share to Calcium Channels
Share to Mutation
Share to Nystagmus, Pathologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34085110
DOI: 10.1007/s10072-021-05368-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports.PMID 34085110Read ↗

[Missense mutation R1345Q in CACNA1A gene causes a new type of ataxia with episodic tremor: clinical features, genetic analysis and treatment in a familial case].Semantic proximity Read ↗

Clinical features and CACNA1A gene mutation in a family with episodic ataxia type 2.Semantic proximity Read ↗

Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature.Semantic proximity Read ↗

A case of novel CACNA1A mutation causing type 2 episodic ataxia.Semantic proximity Read ↗

Episodic ataxia type 2.Semantic proximity Read ↗

High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2.Semantic proximity Read ↗

Identification of two novel mutations in the CACNA1A gene responsible for episodic ataxia type 2.Semantic proximity Read ↗

Misleading EEG in CACNA1A mutation: A case of late-onset episodic ataxia type 2.Semantic proximity Read ↗

A Novel Frameshift CACNA1A Mutation Causing Episodic Ataxia Type 2.Semantic proximity Read ↗

The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.Semantic proximity Read ↗

Acetazolamide improves neurotological abnormalities in a family with episodic ataxia type 2 (EA-2).Semantic proximity Read ↗

Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.